SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is currently drawing significant attention as investors react to its relative strength against Bitcoin and key institutional inflows ahead of upcoming CPI data. The community remains deeply divided, with bulls pointing to historical April performance and potential breakout catalysts, while skeptics warn of persistent market volatility and macroeconomic pressures affecting crypto valuations.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is trending heavily as traders debate the impact of an unexpected public endorsement from President Trump following a significant recent sell-off. While the community is sharply divided between those calling for a short squeeze fueled by institutional accumulation and skeptics echoing Michael Burry's warnings about valuation and competition, the stock remains a major focus due to its critical role in defense-tech infrastructure.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is seeing heavy volatility as traders react to the stock's role as a leveraged Bitcoin proxy amid broader market shifts and recent institutional inflows. The community remains deeply polarized, with active discussions focusing on the sustainability of Bitcoin treasury strategies versus dilution concerns, alongside high-stakes debates over price action and potential short-squeeze catalysts.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is surging following positive topline results from the Phase 2/3 OptimUM-02 trial, where the darovasertib-crizotinib combination significantly improved median progression-free survival in patients with first-line metastatic uveal melanoma. Investors and the biotech community are actively discussing this success as a major de-risking event that positions the company for an accelerated FDA filing and potential transition into a commercial-stage organization.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is seeing heavy retail and institutional interest as investors bet on the company's electro-optic polymer technology as a scalable solution for AI data centers. The community is actively debating the transition from R&D to foundry-integrated manufacturing, with recent partnerships and expectations of upcoming tape-out results driving volatility and ongoing speculation about potential major industry acquisitions.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is seeing massive momentum driven by a recent integration with World Liberty Financial and expanding interest in its unique Web3 music and live event ecosystem. While the community is actively debating its parabolic rise and long-term potential for utility-based growth, many are also expressing caution regarding potential volatility and the risks inherent in such a rapid, hype-driven price surge.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The SPY is experiencing significant volatility driven by the U.S. government's announcement of a naval blockade in the Strait of Hormuz following the collapse of diplomatic talks with Iran. The community is sharply divided, with bulls betting on a quick market recovery despite geopolitical tensions, while bears point to the blockade as a major escalation that threatens global energy supply chains and complicates the broader macro outlook.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is attracting significant investor attention as it progresses through multiple clinical catalysts, including upcoming trial updates for pancreatic and skin cancer. The community remains highly bullish, frequently pointing to strong institutional accumulation, a robust cash position without debt, and multiple analyst price target increases as reasons to accumulate shares before upcoming data readouts.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and community members react to reports of a planned U.S. naval blockade in the Strait of Hormuz, fueling intense debate over global energy security and potential market volatility. Discussions are heavily polarized, with supporters praising the administration's aggressive geopolitical stance while critics express significant concern over the economic impact, diplomatic fallout, and the stability of the current presidential term.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is surging following a strategic two-billion-dollar investment and partnership with NVIDIA, which aims to integrate Marvell's custom silicon and optical technology into NVIDIA's AI infrastructure. The community is actively discussing the stock's role in the AI data center "supercycle," with bullish sentiment driving significant call volume as investors track its potential to hit new highs amid high institutional interest.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are presently covering the firm...

Capricorn Fund Managers Ltd Decreases Position in Tarsus Pharmaceuticals, Inc. $TARS

Capricorn Fund Managers Ltd lessened its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 90.8% during the 4th quarter, according to the company in its most recent Form 13F...

Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Tarsus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday...

Q2 EPS Estimate for Tarsus Pharmaceuticals Lifted by Analyst

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Lifesci Capital increased their Q2 2026 EPS estimates for shares of Tarsus Pharmaceuticals in a research note issued on Tuesday, March 24th...

Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lessened its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 9.6% in the 4th quarter, according to the company in its most recent 13F...

Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade

Key PointsAn executive at Tarsus Pharmaceuticals sold 12,274 shares for a transaction value of approximately $839,000, based on a weighted average price of $68.36 per share across three days ending March 19, 2026...

Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells $761,676.24 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) CEO Bobak Azamian sold 10,972 shares of the firm's stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $69.42, for a total value of $761,676.24. Following the completion of the transaction, the...

Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Elizabeth Yeu Lin Sells 390 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Elizabeth Yeu Lin sold 390 shares of the firm's stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total value of $26,130.00. Following the sale, the insider directly owned...

Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Elizabeth Yeu Lin Sells 375 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Elizabeth Yeu Lin sold 375 shares of the business's stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $69.42, for a total transaction of $26,032.50. Following the transaction...

Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $26,041.09 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Elizabeth Yeu Lin sold 379 shares of the company's stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $68.71, for a total transaction of $26,041.09. Following the completion of the...

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Current Price	$72.56
Prev Close	$72.43
Open	$72.72
Dividend Yield	0.00%
50-Day Moving Average	$68.64
Beta	0.75
Avg. Volume	509,680.50
PE Ratio	-45.08

52-Week High	$85.25
52-Week Low	$38.51
Market Capitalization	$3.09B
EPS (Annual)	-$1.59
Price to Book	8.99
Revenue Per Employee	$1.22M

TARS
Tarsus Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TARS News

TARSTarsus Pharmaceuticals Inc